NCT02649465View on ClinicalTrials.gov

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 11, 2015

Primary Completion Date

December 28, 2020

Study Completion Date

June 30, 2021

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Tofogliflozin

The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks

DRUG

Glimepiride

Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.

Trial Locations (1)

920-8640

Kanazawa University Graduate School of Medical Sciences, Kanazawa

All Listed Sponsors
collaborator

Kowa Company, Ltd.

INDUSTRY

lead

Kanazawa University

OTHER

NCT02649465 - SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD | Biotech Hunter | Biotech Hunter